Canagliflozin for the treatment of adults with Type 2 diabetes
Adultos
- Autores:
-
Aschner Montoya, Pablo
- Tipo de recurso:
- Review article
- Fecha de publicación:
- 2013
- Institución:
- Pontificia Universidad Javeriana
- Repositorio:
- Repositorio Universidad Javeriana
- Idioma:
- eng
- OAI Identifier:
- oai:repository.javeriana.edu.co:10554/53144
- Acceso en línea:
- https://www.openaccessjournals.com/abstract/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes-8095.html
http://hdl.handle.net/10554/53144
- Palabra clave:
- Rights
- License
- Atribución-NoComercial 4.0 Internacional
| id |
JAVERIANA2_967956609f6ff3a4e10bca1fe5f8ff0b |
|---|---|
| oai_identifier_str |
oai:repository.javeriana.edu.co:10554/53144 |
| network_acronym_str |
JAVERIANA2 |
| network_name_str |
Repositorio Universidad Javeriana |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Canagliflozin for the treatment of adults with Type 2 diabetes |
| title |
Canagliflozin for the treatment of adults with Type 2 diabetes |
| spellingShingle |
Canagliflozin for the treatment of adults with Type 2 diabetes |
| title_short |
Canagliflozin for the treatment of adults with Type 2 diabetes |
| title_full |
Canagliflozin for the treatment of adults with Type 2 diabetes |
| title_fullStr |
Canagliflozin for the treatment of adults with Type 2 diabetes |
| title_full_unstemmed |
Canagliflozin for the treatment of adults with Type 2 diabetes |
| title_sort |
Canagliflozin for the treatment of adults with Type 2 diabetes |
| dc.creator.fl_str_mv |
Aschner Montoya, Pablo |
| dc.contributor.author.none.fl_str_mv |
Aschner Montoya, Pablo |
| dc.contributor.corporatename.none.fl_str_mv |
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Endocrinología |
| description |
Adultos |
| publishDate |
2013 |
| dc.date.created.none.fl_str_mv |
2013 |
| dc.date.accessioned.none.fl_str_mv |
2021-03-01T20:26:15Z |
| dc.date.available.none.fl_str_mv |
2021-03-01T20:26:15Z |
| dc.type.local.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_dcae04bc |
| format |
http://purl.org/coar/resource_type/c_dcae04bc |
| dc.identifier.spa.fl_str_mv |
https://www.openaccessjournals.com/abstract/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes-8095.html |
| dc.identifier.issn.spa.fl_str_mv |
1758-1907 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/10554/53144 |
| dc.identifier.instname.spa.fl_str_mv |
instname:Pontificia Universidad Javeriana |
| dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional - Pontificia Universidad Javeriana |
| dc.identifier.repourl.spa.fl_str_mv |
repourl:https://repository.javeriana.edu.co |
| url |
https://www.openaccessjournals.com/abstract/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes-8095.html http://hdl.handle.net/10554/53144 |
| identifier_str_mv |
1758-1907 instname:Pontificia Universidad Javeriana reponame:Repositorio Institucional - Pontificia Universidad Javeriana repourl:https://repository.javeriana.edu.co |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationstartpage.spa.fl_str_mv |
343 |
| dc.relation.citationendpage.spa.fl_str_mv |
350 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Diabetes Management |
| dc.relation.citationvolume.spa.fl_str_mv |
3 |
| dc.relation.citationissue.spa.fl_str_mv |
4 |
| dc.rights.licence.*.fl_str_mv |
Atribución-NoComercial 4.0 Internacional |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
Atribución-NoComercial 4.0 Internacional http://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| dc.format.spa.fl_str_mv |
PDF |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| institution |
Pontificia Universidad Javeriana |
| bitstream.url.fl_str_mv |
http://repository.javeriana.edu.co/bitstream/10554/53144/1/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes.pdf http://repository.javeriana.edu.co/bitstream/10554/53144/2/license.txt http://repository.javeriana.edu.co/bitstream/10554/53144/3/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes.pdf.jpg |
| bitstream.checksum.fl_str_mv |
5481277cd0e942069f89992a3248bc98 2070d280cc89439d983d9eee1b17df53 379b44b51039ef8def6e48405e989f2f |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional - Pontificia Universidad Javeriana |
| repository.mail.fl_str_mv |
repositorio@javeriana.edu.co |
| _version_ |
1811671265132412928 |
| spelling |
Atribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2Aschner Montoya, PabloPontificia Universidad Javeriana. Facultad de Medicina. Departamento de Endocrinología2021-03-01T20:26:15Z2021-03-01T20:26:15Z2013https://www.openaccessjournals.com/abstract/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes-8095.html1758-1907http://hdl.handle.net/10554/53144instname:Pontificia Universidad Javerianareponame:Repositorio Institucional - Pontificia Universidad Javerianarepourl:https://repository.javeriana.edu.coPDFapplication/pdfengCanagliflozin for the treatment of adults with Type 2 diabetesArtículo de revistahttp://purl.org/coar/resource_type/c_dcae04bcAdultosCanagliflozin is a competitive, reversible and potent inhibitor of SGLT2 that lowers the renal threshold for glucose and consequently increases urinary glucose excretion in people with Type 2 diabetes with a blood glucose level above 70–90 mg/dl. Its oral administration in daily doses of 100 and 300 mg in onotherapy, dual therapy or triple therapy including insulin produces a mean HbA1c reduction of 0.7 and 0.85%, respectively, when compared with placebo, a similar reduction to sitagliptin and glimepiride. There is also a modest reduction in weight with both doses. The main adverse effects are genital fungal infections, particularly in women, and, less frequently, urinary tract infections.https://orcid.org/0000-0002-6860-3620N/A343350Diabetes Management34ORIGINALcanagliflozin-for-the-treatment-of-adults-with-type-2-diabetes.pdfcanagliflozin-for-the-treatment-of-adults-with-type-2-diabetes.pdfArtículoapplication/pdf640041http://repository.javeriana.edu.co/bitstream/10554/53144/1/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes.pdf5481277cd0e942069f89992a3248bc98MD51open accessLICENSElicense.txtlicense.txttext/plain; charset=utf-82603http://repository.javeriana.edu.co/bitstream/10554/53144/2/license.txt2070d280cc89439d983d9eee1b17df53MD52open accessTHUMBNAILcanagliflozin-for-the-treatment-of-adults-with-type-2-diabetes.pdf.jpgcanagliflozin-for-the-treatment-of-adults-with-type-2-diabetes.pdf.jpgIM Thumbnailimage/jpeg9166http://repository.javeriana.edu.co/bitstream/10554/53144/3/canagliflozin-for-the-treatment-of-adults-with-type-2-diabetes.pdf.jpg379b44b51039ef8def6e48405e989f2fMD53open access10554/53144oai:repository.javeriana.edu.co:10554/531442021-10-22 14:55:38.035Repositorio Institucional - Pontificia Universidad Javerianarepositorio@javeriana.edu.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 |